Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

46.59 -1.59 (-3.30%)
Official Closing Price Updated: 7:00 PM EDT, May 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 16,884,212
Open 47.30
Bid (Size) 46.65 (1)
Ask (Size) 46.69 (2)
Prev. Close 48.18
Today's Range 46.51 - 47.62
52wk Range 39.35 - 63.33
Shares Outstanding 2,222,113,553
Dividend Yield 5.32%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Bristol-Myers Squibb Strikes $350 Million Deal To End Hawaii's Plavix Lawsuit
Bristol-Myers Squibb will pay $350 million to settle Hawaii's lawsuit over Plavix marketing practices, ending claims without admitting wrongdoing and avoiding trial. 
Via Benzinga
Topics Lawsuit
Exposures Financial Legal
Top Biotech Halozyme Undercuts Its Breakout On Bad Medicare News
It's biggest product will be up for price negotiations under the Inflation Reduction Act much sooner than expected. 
Via Investor's Business Daily
Topics Economy Government
Exposures Interest Rates Political

Performance

YTD
-18.0%
-18.0%
1 Month
-9.3%
-9.3%
3 Month
-16.1%
-16.1%
6 Month
-22.1%
-22.1%
1 Year
+3.4%
+3.4%

More News

Read More
Market Monitor News May 12 ( NRG Energy, Amazon, Meta Platforms UP - CVS Health DOWN)
Via Chartmill
Topics Government World Trade
Exposures Political Tariff
Merck, Pfizer, Eli Lilly Stocks Rebound As Trump Targets Drug Costs With New Executive Order
Via Stocktwits
Topics Government
Exposures Political
S&P 500, Dow Jones Pharma Stocks Boomerang As Trump Threatens Drug-Price Reform
Via Investor's Business Daily
Topics Government Stocks
Exposures Political US Equities
EXCLUSIVE: FDA Clears Lantern Pharma's Planned Phase 1b/2 Trial of LP-184 In Treatment-Resistant Lung Cancer Patients
Via Benzinga
Exposures Product Safety
Cathie Wood Says AI Innovation In Healthcare Will Be More 'Profound' Than Autonomous Taxi Networks, Humanoid Robots
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
BMY Q1 Earnings Call: Growth Portfolio Offsets Declines, Guidance Raised Amid Pipeline Advancements
Via StockStory
Trump's New Drug Pricing Executive Order Could Rattle Pharma Stocks, With Price Cuts Of Up To 80%: Novo Nordisk, Pfizer And J&J Fall In Premarket
Via Benzinga
Topics Government
Exposures Political
BRISTOL-MYERS SQUIBB CO (NYSE:BMY) stands out as a stock that provides good value for the fundamentals it showcases.
Via Chartmill
3 Healthcare Stocks in Hot Water
Via StockStory
Topics Economy Stocks
Exposures COVID-19 Supply Chain US Equities
A Look Into Bristol-Myers Squibb Inc's Price Over Earnings
Via Benzinga
Top gainers and losers in the S&P500 index during Wednesday's after-hours session.
Via Chartmill
FDA Expands Surprise Inspections At Foreign Drug And Food Facilities, Targets Double Standards In Overseas Manufacturing Oversight
Via Benzinga
Exposures Product Safety
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
Bristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer
From Bristol Myers Squibb
Via Business Wire
FDA Pushes Potential Approval For Cytokinetics' Experimental Heart Drug By Three Months
Via Benzinga
Exposures Product Safety
1 Stock Under $50 with Solid Fundamentals and 2 to Keep Off Your Radar
Via StockStory
Bristol-Myers Squibb Co (NYSE:BMY): A High-Yield Dividend Stock Worth Considering
Via Chartmill
This High-Yield Pharma Stock Looks Like an Incredible Bargain
Via The Motley Fool
Topics Intellectual Property
Exposures Intellectual Property
Don’t Be Fooled by the Bounce: The Market Storm Isn’t Over Yet
Via MarketBeat
Topics Economy Government World Trade
Exposures Interest Rates Political Tariff
Large Cap Biopharmaceutical Update: Mixed Performance As Tariffs Loom
Via Talk Markets
Topics ETFs Stocks / Equities
Top 3 Health Care Stocks That May Rocket Higher In April
Via Benzinga
Pfizer (PFE) Reports Q1: Everything You Need To Know Ahead Of Earnings
Via StockStory
Topics Government World Trade
Exposures Political Tariff
4 Surefire Dividend Stocks to Buy in the Stock Market Sell-Off
Via The Motley Fool
Topics Economy Intellectual Property World Trade
Exposures Economy Intellectual Property Tariff

Frequently Asked Questions

Is Bristol-Myers Squibb publicly traded?
Yes, Bristol-Myers Squibb is publicly traded.
What exchange does Bristol-Myers Squibb trade on?
Bristol-Myers Squibb trades on the New York Stock Exchange
What is the ticker symbol for Bristol-Myers Squibb?
The ticker symbol for Bristol-Myers Squibb is BMY on the New York Stock Exchange
What is the current price of Bristol-Myers Squibb?
The current price of Bristol-Myers Squibb is 46.59
When was Bristol-Myers Squibb last traded?
The last trade of Bristol-Myers Squibb was at 05/13/25 07:00 PM ET
What is the market capitalization of Bristol-Myers Squibb?
The market capitalization of Bristol-Myers Squibb is 103.53B
How many shares of Bristol-Myers Squibb are outstanding?
Bristol-Myers Squibb has 104B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.